INmune Bio, Inc.

NASDAQ
INMB
Stock
Yield per half year: +58.59%
Dividend yield: 0%
Sector: Healthcare

7.76 $

+0.105 $ +1.37%
4.4 $
10.48 $

Min/max per year

Share chart INmune Bio, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About INmune Bio, Inc.

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

more details
The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2019-02-04
ISIN US45782T1051
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Change price per day: +1.37% (7.65)
Change price per week: +3.95% (7.46)
Change price per month: -1.84% (7.9)
Change price per 3 month: -0.5769% (7.8)
Change price per half year: +58.59% (4.89)
Change price per year: -23.6% (10.15)
Change price per 3 year: +25.69% (6.17)
Change price per 5 year: +63.26% (4.75)
Change price per year to date: +72.72% (4.49)
All parameters

Grade

Underestimation
Title Value Grade
P/S 1220.37 1
P/BV 4.96 3
P/E 0 0
Efficiency
Title Value Grade
ROA, % -52.64 0
ROE, % -78.68 0
ROIC, % 0 0
Dividends
Title Value Grade
Dividend yield 0 0
DSI 0 0
Average dividend growth 0 0
Debt
Title Value Grade
Debt/EBITDA -0.3509 10
Debt/Ratio 0.1831 10
Debt/Equity 0.4946 10
Growth impulse
Title Value Grade
Yield Revenue, % -99.8 0
Yield Ebitda, % 175.38 10
Yield EPS, % 87.52 9
More

Main owners

Institutions Volume Share, %
Vanguard Group Inc 541 329 3
Blackrock Inc. 257 929 1.43
Rhenman & Partners Asset Management AB 178 284 0.99
Geode Capital Management, LLC 170 040 0.94
Janney Montgomery Scott LLC 163 559 0.91
Deutsche Bank Aktiengesellschaft 109 848 0.61
MAI Capital Management 98 012 0.54
Quadrant Capital Group LLC 60 000 0.33
Royal Bank of Canada 57 791 0.32
State Street Corporation 45 063 0.25

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Dr. Raymond Joseph Tesi M.D. Co-Founder, President, CEO, Chief Medical Officer & Chairman 500.5k 1956 (69 years)
Mr. David J. Moss M.B.A. CFO, Treasurer & Secretary 394.9k 1970 (55 years)
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Chief Scientific Officer & Chief Manufacturing Officer 150.24k 1963 (62 years)
Mr. Joshua S. Schoonover Esq. General Counsel N/A

About company

Address: United States, Boca Raton. FL, 225 NE Mizner Blvd. - Open in google maps, Open in yandex maps
Website: https://www.inmunebio.com